Parkinson's stem-cell success claims vary widely across uncontrolled trials — some report motor-score 'improvement' in a portion of patients, others minimal change. No placebo-controlled trial has set a consensus rate. Reported gains are usually modest (small reductions in tremor or rigidity on rating scales) and do not equal major functional independence. Distinguishing effect from natural fluctuation or concurrent levodopa is problematic.
Sixty-nine registered trials and 16 recruiting studies investigate stem-cell approaches in Parkinson's. Small series document modest motor-symptom changes within 6–12 months, but are typically unblinded, single-arm, and lack sham controls. A few report dopamine-replacement activity on PET imaging; durability beyond 12 months is sparse. Heterogeneous cell products and delivery routes complicate interpretation. No trial has prevented progression or restored motor function to pre-disease levels.
Am I a candidate? → · Parkinson's Disease: full overview → · Parkinson's Disease cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment